Reports of tecovirimat-resistant mpox have emerged after widespread use of antiviral therapy during the 2022 mpox outbreak. Optimal management of patients with persistent infection with or without suspected resistance is yet to be established. We report a successfully treated case of severe mpox in California, USA, that had suspected tecovirimat resistance.
Keywords: HIV/AIDS; MPX; MPXV; United States; antiviral drug; drug resistance; human immunodeficiency virus; monkeypox; monkeypox virus; mpox; severe infection; tecovirimat; tecovirimat resistance; viruses.